{{Drugbox
| verifiedrevid = 462248957
| IUPAC_name = 5-amino-2-hydroxybenzoic acid
| image = Mesalazine structure.svg
| width = 171

<!--Clinical data-->
| tradename = Pentasa, Asacol, Canasa, Rowasa, Lialda, Apriso, Salofalk
| Drugs.com = {{drugs.com|monograph|mesalamine}}
| pregnancy_US = B
| pregnancy_category =
| legal_US = Rx-only
| legal_status =
| routes_of_administration = oral, [[rectal]]
| licence_US = Mesalazine
| MedlinePlus = a688021
| DailyMedID = 47586

<!--Pharmacokinetic data-->
| bioavailability = orally: 20-30% absorbed<br>rectally: 10-35%
| metabolism = Rapidly & extensively metabolised intestinal mucosal wall and the liver
| elimination_half-life = 5 hours after initial dose.<br>At steady state 7 hours
| excretion =

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 89-57-6
| ATC_prefix = A07
| ATC_suffix = EC02
| PubChem = 4075
| IUPHAR_ligand = 2700
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00244
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3933
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4Q81I59GXC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00377
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6775
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 704

<!--Chemical data-->
| C=7 | H=7 | N=1 | O=3 
| molecular_weight = 153.135 g/mol
| smiles = O=C(O)c1cc(ccc1O)N
| InChI = 1/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
| InChIKey = KBOPZPXVLCULAV-UHFFFAOYAE
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KBOPZPXVLCULAV-UHFFFAOYSA-N
}}

'''Mesalazine''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]), also known as '''mesalamine''' ([[United States Adopted Name|USAN]]) or '''5-aminosalicylic acid''' (5-ASA), is an [[anti-inflammatory]] [[medication|drug]] used to treat [[inflammatory bowel disease]], such as [[ulcerative colitis]]<ref>{{cite pmid|11709512}}</ref> and mild-to-moderate [[Crohn's disease]].<ref>
{{cite journal
| author = Sandborn WJ, Feagan BG, Lichtenstein GR
| title = Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission
| journal = Alimentary Pharmacology & Therapeutics
| volume = 26
| issue = 7
| pages = 987–1003
| year = 2007
| month = October
| pmid = 17877506
| doi = 10.1111/j.1365-2036.2007.03455.x
| url = http://www3.interscience.wiley.com/cgi-bin/fulltext/117987903/HTMLSTART
| accessdate = 2009-12-20
}}</ref> Mesalazine is a bowel-specific [[aminosalicylate]] drug that acts locally in the gut and has its predominant actions there, thereby having few systemic side effects.<ref name="PharmGKB">[http://www.pharmgkb.org/drug/PA450384#tabview=tab2&subtab=31 "mesalazine"]. PharmGKB.</ref> 

As a derivative of [[salicylic acid]], mesalazine is also thought to be an [[antioxidant]] that traps [[free radicals]], which are potentially damaging byproducts of metabolism.<ref name="PharmGKB" />

Mesalazine is considered the active [[Functional group|moiety]] of [[sulfasalazine]], which is metabolized to [[sulfapyridine]] and mesalazine.<ref>''Lippencott's Illustrated Reviews: Pharmacology'', 4th Ed. Finkel, Cubeddu and Clark</ref>

==Side effects==
{{refimprove section|date=May 2012}}
Commonly:
* Diarrhea 
* Nausea
* Cramping 
* Flatulence<ref name="Lialda">{{cite web | title = Lialda Side Effects & Safety Information| url=http://www.lialda.com/aboutLialda/sideEffect.asp | year = 2007 | month= October | publisher=Shire US | accessdate=2008-01-07}}</ref>

Uncommonly:
* [[Headache]]
* Exacerbation of the colitis 
* Hypersensitivity reactions (including rash, [[urticaria]] aka hives, [[interstitial nephritis]] and [[lupus erythematosus]]-like syndrome)
* Hair loss

Rarely:
* Acute [[pancreatitis]]
* [[Hepatitis]]
* [[Nephrotic syndrome]]
* Blood disorders (including [[agranulocytosis]], [[aplastic anaemia]], [[leukopenia]], [[neutropenia]], [[thrombocytopenia]])
* Fever <ref name="Desensitization after fever induced by mesalazine">{{cite web | title = Desensitization after fever induced by mesalazine| url=http://onlinelibrary.wiley.com/doi/10.1034/j.1398-9995.1999.00298.x/full | year = 2001 | month= December | accessdate=2001-12-24}}</ref>

Mesalazine avoids the sulfonamide side effects of [[sulfasalazine]] (which contains additional [[sulfapyridine]]), but carries additional rare risks of: 
* Allergic lung reactions
* Allergic [[myocarditis]]
* [[Methaemoglobinaemia]]

==Monitoring==
{{Unreferenced section|date=November 2009}}
As a result of the small risks of kidney, liver and blood disorders, blood tests should be taken before and after starting treatment. Patients are advised to report any unexplained bleeding, bruising, [[purpura]], sore throat, fever or [[malaise]] that occurs during treatment so that a [[full blood count]] can be urgently taken.

==Formulations==
{{Unreferenced section|date=November 2009}}
[[File:000863lg Pentasa 250 mg.jpg|right|thumb|upright|Pentasa 250 MG Extended Release Capsule]]
Mesalazine is formulated for oral ingestion as tablets or granules, and for rectal administration as a rectal [[suppository]], suspension or [[enema]]s.{{Citation needed|date=December 2011}} It is marketed under a variety of brand names:{{Citation needed|date=December 2011}}

*UK: '''Asacol''', '''Ipocal''', '''Pentasa''', '''Salofalk''', '''Mezavant XL'''
*Ireland: '''Asacolon''', '''Pentasa''', '''Salofalk''', '''Mezavant XL'''
*France: '''Asacol''', '''Pentasa''', '''Mezavant'''
*US: '''Canasa''', '''Rowasa''', '''Pentasa''', '''Asacol''',  '''Delzicol''', '''Lialda''', '''Apriso''', '''Salofalk'''
*Spain / España: '''Pentasa''', '''Claversal''', '''Lixacol''', '''Mezavant''', '''Salofalk'''
*Canada: '''Asacol''', '''Pentasa''', '''Salofalk''', '''Mezavant'''
*India: '''Mesacol''', '''VEGAZ-OD'''.
*Mexico: '''Salofalk'''
*Serbia: '''Salofalk'''
*Uruguay: '''Mesacron''', '''Mesalazina'''
*Brazil: '''Mesalazina''', '''Mesalazina Enema''', '''Mesacol''', '''Mesacol MNX''', '''Asalit''', 
*Australia: '''Mesasal'''
*Egypt: '''Pentasa''', '''Salofalk'''
'''Chron-asa 5''', '''Pentasa''', '''Pentasa Enema''', '''Mesaneo'''

Dosing depends on the preparation used; in particular, slow-release tablets may have quite different drug delivery characteristics and are not interchangeable.{{Citation needed|date=December 2011}}

Preparations that lower stool pH (such as [[lactulose]], a laxative) will possibly affect the binding of mesalazine in the bowel and will therefore reduce its efficacy.{{Citation needed|date=December 2011}}

==References==
{{reflist|30em}}
* {{cite book | editor-last = Mehta | editor-first = Dinesh K | title=[[British National Formulary]] | volume=45 | month=March | year = 2003 | publisher=Pharmaceutical Press | location=London | isbn= 0-85369-555-5 | author= }}
* {{cite book | editor-last = Sweetman | editor-first = Sean C | title=[[Martindale: The complete drug reference]] | edition=34th | month=November | year = 2004 | publisher=Pharmaceutical Press | location=London | isbn= 0-85369-550-4 | author= }}

==External links==
* {{cite doi|10.1053/jcgh.2003.50001}}
* [http://www.ccfa.org/reuters/mesalamine "Novel formulation increases efficacy of mesalamine for treating ulcerative colitis"]. Reuters. February 16, 2007.
* [http://www.ccfa.org/reuters/mesalazine "Once daily mesalazine effective in active ulcerative colitis: study"]. Reuters. January 30, 2009.
* [http://www.pentasaus.com/ Pentasa Official Site]
* [http://www.asacol.com/ Asacol Official Site]
* [http://www.lialda.com/ Lialda Official Site]
* [http://www.apriso-uc.com/ Apriso Official Site]
* [http://pi.shirecontent.com/PI/PDFs/Pentasa_USA_ENG.pdf Pentasa Full Prescribing Information] Shire
* [http://www.asacol.com/pdf/asacol-info.pdf Asacol Full Prescribing Information] Warner Chilcott
* [http://pi.shirecontent.com/PI/PDFs/Lialda_USA_ENG.pdf Lialda Full Prescribing Information] Shire
* [http://www.aprisorx.com/assets/pdf/apriso-pi.pdf Apriso Full Prescribing Information]  [[Salix Pharmaceuticals]]

{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}

[[Category:Anilines]]
[[Category:Anti-inflammatory agents]]
[[Category:Gastroenterology]]
[[Category:Salicylic acids]]
[[Category:Antioxidants]]